197:"Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells"
66:. At low (picomolar) concentrations, EGF promotes cell growth of A431 cells whereas at higher (nanomolar) concentrations it inhibits growth by causing the cells to terminally
414:"High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening"
285:
Lamb DJ, Spotts GS, Shubhada S, Baker KR (August 1991). "Partial characterization of a unique mitogenic activity secreted by rat
Sertoli cells".
328:
MacLeod CL, Luk A, Castagnola J, Cronin M, Mendelsohn J (April 1986). "EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells".
87:
115:
479:
78:
secreted growth factor (SCSGF) strongly induces cell proliferation. Stimulation of A431 cells with
67:
44:
131:
36:
8:
24:
438:
413:
353:
310:
221:
196:
119:
262:
245:
443:
394:
345:
302:
298:
267:
226:
357:
314:
246:"Partial characterization of a unique growth factor secreted by human Sertoli cells"
181:
433:
425:
384:
373:"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients"
337:
294:
257:
216:
208:
156:
and protein synthesis. The A431 lines engineered to express tumor antigens such as
389:
372:
153:
143:
142:, A431 cells have shown antitumorigenic properties of introduced EGF and related
123:
111:
107:
51:
212:
79:
473:
83:
55:
447:
398:
341:
230:
75:
349:
306:
271:
464:
429:
371:
Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I (May 2005).
157:
99:
71:
139:
63:
40:
20:
195:
Graness A, Hanke S, Boehmer FD, Presek P, Liebmann C (April 2000).
148:
74:
reduces basal and EGF-induced EGFR phosphorylation. Treatment with
62:
which control cellular processes such as growth, proliferation and
48:
135:
59:
103:
164:
have been made as cell models to test cancer therapeutics.
152:
studies have found EGF to also cause substantial lowering of
182:"A431 - Cytokines and Cells Online Pathfinder Encyclopaedia"
161:
327:
412:
Phung Y, Gao W, Man YG, Nagata S, Ho M (September 2012).
194:
127:
284:
244:
Buch JP, Lamb DJ, Lipshultz LI, Smith RG (April 1988).
243:
411:
370:
471:
188:
437:
388:
261:
220:
278:
237:
93:
47:stimulation of A431 cells induces rapid
116:Epidermal growth factor receptor (EGFR)
472:
98:A431 cells are used in studies of the
43:) of an 85- year-old female patient.
287:Molecular and Cellular Endocrinology
118:. They are often used as a positive
35:A431 cells were established from an
174:
13:
30:
14:
491:
458:
70:. Treatment of A431 cells with
23:(epidermoid carcinoma) used in
405:
364:
330:Journal of Cellular Physiology
321:
134:, and are highly sensitive to
114:abnormally high levels of the
1:
390:10.1158/1078-0432.CCR-04-2304
263:10.1016/S0015-0282(16)59836-7
167:
126:. They contain no functional
45:Epidermal growth factor (EGF)
299:10.1016/0303-7207(91)90089-B
7:
10:
496:
465:Cellosaurus entry for A431
213:10.1042/0264-6021:3470441
377:Clinical Cancer Research
250:Fertility and Sterility
201:The Biochemical Journal
146:characteristics. Other
144:radiation sensitization
342:10.1002/jcp.1041270121
82:induces expression of
132:tumor suppressor gene
94:Research Applications
110:pathways since they
37:epidermoid carcinoma
25:biomedical research
430:10.4161/mabs.20933
19:are a model human
86:-related protein
487:
480:Human cell lines
452:
451:
441:
409:
403:
402:
392:
368:
362:
361:
325:
319:
318:
282:
276:
275:
265:
241:
235:
234:
224:
192:
186:
185:
178:
495:
494:
490:
489:
488:
486:
485:
484:
470:
469:
461:
456:
455:
410:
406:
383:(10): 3814–20.
369:
365:
326:
322:
283:
279:
242:
238:
207:(Pt 2): 441–7.
193:
189:
180:
179:
175:
170:
154:DNA replication
108:cell signalling
96:
52:phosphorylation
33:
31:Characteristics
12:
11:
5:
493:
483:
482:
468:
467:
460:
459:External links
457:
454:
453:
404:
363:
320:
277:
236:
187:
172:
171:
169:
166:
95:
92:
80:phorbol esters
32:
29:
9:
6:
4:
3:
2:
492:
481:
478:
477:
475:
466:
463:
462:
449:
445:
440:
435:
431:
427:
423:
419:
415:
408:
400:
396:
391:
386:
382:
378:
374:
367:
359:
355:
351:
347:
343:
339:
336:(1): 175–82.
335:
331:
324:
316:
312:
308:
304:
300:
296:
293:(1–3): 1–12.
292:
288:
281:
273:
269:
264:
259:
256:(4): 658–65.
255:
251:
247:
240:
232:
228:
223:
218:
214:
210:
206:
202:
198:
191:
183:
177:
173:
165:
163:
159:
155:
151:
150:
145:
141:
137:
133:
129:
125:
121:
117:
113:
109:
105:
101:
91:
89:
85:
84:interleukin 1
81:
77:
73:
69:
68:differentiate
65:
61:
57:
56:intracellular
53:
50:
46:
42:
39:in the skin (
38:
28:
26:
22:
18:
424:(5): 592–9.
421:
417:
407:
380:
376:
366:
333:
329:
323:
290:
286:
280:
253:
249:
239:
204:
200:
190:
176:
147:
138:stimuli. In
106:-associated
97:
76:Sertoli cell
34:
16:
15:
130:, a potent
168:References
158:mesothelin
140:xenografts
124:expression
100:cell cycle
72:bradykinin
58:signaling
17:A431 cells
136:mitogenic
122:for EGFR
64:apoptosis
41:epidermis
21:cell line
474:Category
448:22820551
399:15897581
358:19448225
315:23996107
231:10749673
149:in vitro
60:proteins
49:tyrosine
439:3499300
350:3007537
307:1936536
272:3350161
222:1220976
120:control
112:express
446:
436:
397:
356:
348:
313:
305:
270:
229:
219:
104:cancer
354:S2CID
311:S2CID
444:PMID
418:mAbs
395:PMID
346:PMID
303:PMID
268:PMID
227:PMID
162:GPC3
160:and
102:and
88:IL1H
434:PMC
426:doi
385:doi
338:doi
334:127
295:doi
258:doi
217:PMC
209:doi
205:347
128:p53
54:of
476::
442:.
432:.
420:.
416:.
393:.
381:11
379:.
375:.
352:.
344:.
332:.
309:.
301:.
291:79
289:.
266:.
254:49
252:.
248:.
225:.
215:.
203:.
199:.
90:.
27:.
450:.
428::
422:4
401:.
387::
360:.
340::
317:.
297::
274:.
260::
233:.
211::
184:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.